Navidea announces data from Lymphoseek Phase 3 study on oral and squamous cell cancer

[News]

Navidea Biopharmaceuticals, Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical study investigating 99m-Tc-Tilmanocept in oral and squamous cell cancers (SCC) were presented as a poster presentation at the 65th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Orlando, Florida, March 21-24, 2012.

More... (http://www.news-medical.net/news/20120329/Navidea-announces-data-from-Lymphoseek-Phase-3-study-on-oral-and-squamous-cell-cancers.aspx)